tACPAs opens up new avenues for the therapies for RA, but we still don’t know the difference between the B cells that produce pathological ACPA and tACPA, which may be very important for us to understand the role of B cells in RA development. This evidence concerns the gene PRTN3 and rheumatoid arthritis.